Top Page
Covalon Technologies
(COV)
Covalon Technologies (COV) vs. iShares MSCI Canada ETF (EWC)
Covalon Technologies Business Overview & Revenue Model
Covalon Technologies Earnings Call Summary
Covalon Technologies Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.99M | 31.17M | 26.60M | 18.15M | 19.56M | 25.80M |
| Gross Profit | 18.37M | 18.93M | 14.36M | 7.49M | 9.70M | 12.49M |
| EBITDA | 3.18M | 3.14M | -3.56M | -8.11M | 1.54M | -6.63M |
| Net Income | 2.31M | 2.67M | -4.46M | -9.66M | 23.48M | -6.95M |
Balance Sheet | ||||||
| Total Assets | 35.24M | 31.81M | 24.90M | 30.38M | 40.58M | 34.70M |
| Cash, Cash Equivalents and Short-Term Investments | 18.09M | 16.75M | 8.79M | 14.06M | 22.95M | 3.51M |
| Total Debt | 1.28M | 901.67K | 1.56M | 2.17M | 2.59M | 20.90M |
| Total Liabilities | 5.56M | 4.30M | 6.11M | 6.15M | 7.21M | 25.59M |
| Stockholders Equity | 29.68M | 27.50M | 18.79M | 24.23M | 33.37M | 9.11M |
Cash Flow | ||||||
| Free Cash Flow | 4.39M | 3.06M | -4.50M | -9.08M | 443.71K | -4.40M |
| Operating Cash Flow | 5.08M | 3.47M | -3.18M | -7.99M | 621.37K | -4.03M |
| Investing Cash Flow | -556.27K | -281.63K | -81.02K | -843.02K | -278.53K | -370.41K |
| Financing Cash Flow | 5.09M | 4.97M | -2.16M | -2.19M | -8.25M | -1.75M |
Covalon Technologies Technical Analysis
Covalon Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | C$53.19M | 22.99 | 9.01% | ― | 13.00% | ― | |
59 Neutral | C$35.58M | -134.21 | -1.13% | ― | -9.54% | -105.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | ― | ― | ― | ― | ― | ― | |
41 Neutral | C$52.32M | -11.19 | ― | ― | -33.66% | -48.89% | |
33 Underperform | C$44.37M | ― | ― | ― | ― | 55.88% | |
33 Underperform | C$152.02M | -21.22 | -67.18% | ― | ― | 52.62% |
Covalon Technologies Corporate Events
Covalon Technologies Ltd. has announced its first-ever special cash dividend of $0.15 CAD per common share, totaling $4,112,711.55 CAD, to be paid to shareholders on November 18, 2025. This decision reflects the company’s strong financial performance, having been profitable for the last six quarters, and its robust cash position of $18.9 million CAD with no debt. The dividend is intended to reward shareholders and underscores Covalon’s financial health and commitment to shareholder value.
The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.
Covalon Technologies Ltd. announced its participation in the Planet MicroCap Showcase: TORONTO 2025, highlighting its position as a profitable, debt-free, and undervalued healthcare company. CEO Brent Ashton will discuss the company’s ability to outperform larger medical device companies, recent clinical evidence supporting its products, and strategies for leveraging its strong financial position to drive shareholder value and future business success.
The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.
Covalon Technologies announced its participation in the 2025 ANCC National Magnet & Pathway Conference, where it will present its portfolio of patient safety solutions to over 10,000 nurses. The company aims to engage with nursing leaders to advance nursing excellence and improve clinical outcomes, highlighting its VALGuard® Line Guard product, which has shown significant success in reducing CLABSIs in clinical studies.
The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.
Covalon Technologies announced its participation in the APHON 49th Annual Conference, showcasing its leadership in vascular access innovation. The company presented evidence-backed solutions like VALGuard® Line Guard and CovaClear® silicone dressings, which have shown significant reductions in hospital-acquired infections and cost savings. These innovations highlight Covalon’s commitment to advancing pediatric care and enhancing hospital efficiency, reinforcing its position in the medical technology industry.
The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.
Covalon Technologies Ltd. announced the appointment of its largest shareholder, Mr. Abe Schwartz, as the new Chair of the Board, following the departure of Mr. Amir Boloor. Mr. Schwartz, who has a long history with the company and extensive experience in the healthcare and IT industries, aims to introduce new initiatives and drive long-term value creation for stakeholders. This leadership change is expected to further strengthen Covalon’s position in the medical technology industry, as the company is currently profitable, debt-free, and holds $18 million in cash.
The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.
Covalon Technologies Ltd. announced its participation in the Association for Vascular Access 2025 Annual Meeting, showcasing its advanced vascular access and infection prevention solutions. A recent clinical study highlighted the effectiveness of Covalon’s VALGuard® Line Guard in reducing Central Line-Associated Blood Stream Infections, underscoring the company’s commitment to enhancing clinical and economic outcomes for healthcare providers and patients.
The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.
Covalon Technologies announced the publication of a peer-reviewed clinical study demonstrating the effectiveness of its VALGuard® Vascular Access Line Guard in significantly reducing central line-associated bloodstream infections (CLABSIs) in a pediatric hospital setting. The study, conducted at the Children’s Hospital at Montefiore, showed a 100% reduction in CLABSI rates in the Pediatric Critical Care Unit and a 53% reduction in Acute Care Units, highlighting the product’s potential to enhance infection prevention protocols. This publication supports Covalon’s growth strategy in the vascular access and surgical consumables sector and reinforces the importance of advanced technologies in preventing hospital-acquired infections.
The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.
Covalon Technologies’ recent earnings call painted a picture of both optimism and caution. The company reported strong sequential revenue growth, successful international expansion, and a robust cash position, suggesting positive forward momentum. However, concerns were raised due to a year-over-year revenue decline and decreased adjusted EBITDA, though these issues may be mitigated by promising innovations and positive clinical study results.
Covalon Technologies Ltd. reported strong financial results for its fiscal 2025 third quarter, with significant revenue and EBITDA growth. The company achieved a 10.4% increase in quarterly revenue and a 52% rise in adjusted EBITDA, driven by successful strategic initiatives and product adoption. Covalon’s U.S. Vascular Access and Surgical Consumables sales channel experienced record growth, and the company anticipates further acceleration in product adoption due to new clinical evidence studies. The company’s robust financial position, with over $18 million in cash and no debt, positions it well for future expansion and increased market impact.
The most recent analyst rating on (TSE:COV) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.
Covalon Technologies Ltd. has achieved DTC eligibility in the United States, allowing its common shares to be electronically cleared and settled through The Depository Trust Company. This development simplifies trading on the U.S. OTCQX Market, potentially increasing U.S. investor interest and enhancing liquidity. The move is expected to improve Covalon’s positioning in the U.S. market, where similar companies often trade at higher values, thus supporting share price appreciation.
The most recent analyst rating on (TSE:COV) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.
Covalon Technologies announced it will release its third-quarter fiscal 2025 financial results on August 21, 2025, followed by a conference call and webcast to discuss the results. This announcement is significant for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor confidence.
Covalon Technologies Ltd. has announced a conference call to discuss its third quarter fiscal 2025 financial results, scheduled for August 21, 2025. This announcement reflects Covalon’s commitment to transparency and engagement with stakeholders, providing an opportunity for investors and analysts to gain insights into the company’s financial performance and strategic direction.
Covalon Technologies Ltd. announced it will release its third quarter fiscal 2025 financial results on August 21, 2025, followed by a conference call and webcast to discuss these results. This announcement is significant for stakeholders as it provides an opportunity to engage with company management and gain insights into Covalon’s financial performance and strategic direction.